The estimated Net Worth of Greg Zante is at least $20.6 Million dollars as of 29 July 2024. Greg Zante owns over 16,136 units of Viking Therapeutics Inc stock worth over $11,378,373 and over the last 21 years he sold VKTX stock worth over $9,185,802. In addition, he makes $0 as Senior Vice President - Finance and IR Contact Officer at Viking Therapeutics Inc.
Sign up
Greg Zante VKTX stock SEC Form 4 insiders trading
Greg has made over 14 trades of the Viking Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 16,136 units of VKTX stock worth $922,172 on 29 July 2024.
The largest trade he's ever made was selling 161,940 units of Viking Therapeutics Inc stock on 30 March 2023 worth over $2,783,749. On average, Greg trades about 17,158 units every 279 days since 2003. As of 29 July 2024 he still owns at least 187,052 units of Viking Therapeutics Inc stock.
You can see the complete history of Greg Zante stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Greg Zante biography
Greg Zante is the Senior Vice President - Finance, IR Contact Officer at Viking Therapeutics Inc.
What's Greg Zante's mailing address?
Greg's mailing address filed with the SEC is C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121.
Insiders trading at Viking Therapeutics Inc
Over the last 10 years, insiders at Viking Therapeutics Inc have traded over $46,107,976 worth of Viking Therapeutics Inc stock and bought 199,715 units worth $855,627 . The most active insiders traders include Brian Lian, Charles A Jr Rowland, and Marianna Mancini. On average, Viking Therapeutics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $4,137,170. The most recent stock trade was executed by Brian Lian on 21 August 2024, trading 1,000 units of VKTX stock currently worth $7,770.
What does Viking Therapeutics Inc's logo look like?
Complete history of Greg Zante stock trades at Sangamo Therapeutics Inc and Viking Therapeutics Inc
Viking Therapeutics Inc executives and stock owners
Viking Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brian Lian,
President, Chief Executive Officer, Director -
Dr. Brian Lian Ph.D.,
Pres, CEO & Director -
Michael Morneau,
Vice President - Finance and Administration -
S. Kathy Rouan,
Independent Director -
Lawson Macartney,
Independent Chairman of the Board -
Charles Rowland,
Independent Director -
J. Matthew Singleton,
Independent Director -
Matthew Foehr,
Director -
Greg Zante,
Senior Vice President - Finance, IR Contact Officer -
Michael Morneau,
VP of Fin. & Admin. -
Marianne Mancini,
Chief Operating Officer -
Gregory S. Zante,
Chief Financial Officer -
Pharmaceuticals Inc Ligand,
10% owner -
Stephen W Webster,
Director -
Rochelle Hanley,
Chief Medical Officer -
Hiroko Masamune,
Chief Development Officer -
Marianna Mancini,
Chief Operating Officer -
Michael Dinerman,
Chief Operating Officer